Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Cediranib in Glioblastoma

Pp. 176-183 (8)

Elizabeth R. Gerstner, Jorg H. Dietrich, Daphne Wang and Tracy T. Batchelor

Abstract

Targeting tumor-derived angiogenesis has emerged as a promising new treatment strategy in patients with glioblastoma. Cediranib (Recentin™) is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptors and has demonstrated improved progression-free survival in an uncontrolled phase II study of patients with recurrent glioblastoma. The drug is taken orally, once daily, and has a manageable side effect profile. In addition, it has potent anti-edema and steroid-sparing effects that might improve the quality of life of glioblastoma patients. Several clinical trials are ongoing testing cediranib in patients with gliomas.

Affiliation:

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114.